| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 3 | -43,637 | 100% | $14.36 | -$626,701 |
| Net | -3 | -43,637 | -100% | -$626,701 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| JOHNSON & JOHNSON | 10%+ Owner | $33,744,900 | 09 Apr 2024 | ||
| Versant Venture Capital VI, L.P. | 10%+ Owner | $8,931,592 | 09 Apr 2024 | ||
| Daniel S. Lorrain | Chief Scientific Officer | $2,365,919 | -$357,607 | -13% | 02 Mar 2026 |
| Carmine N. Stengone | CEO and President, Director | $239,495 | -$120,128 | -33% | 24 Feb 2026 |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | $218,240 | 31 Jan 2025 | ||
| Tim Watkins | CMO & Head of Development | $0 | -$148,967 | -100% | 02 Mar 2026 |
| Olivia C. Ware | Director | 26 Jun 2025 | |||
| John Stephen Healy | General Counsel and Corp Sec | 30 Jan 2026 | |||
| Sarah Boyce | Director | 26 Jun 2025 | |||
| Gines Diego Miralles | Director | 26 Jun 2025 | |||
| Troy A. Ignelzi | Director | 26 Jun 2025 | |||
| Todd R. Brady | Director | 26 Jun 2025 | |||
| Slover Peter T. | Chief Financial Officer | 30 Jan 2026 | |||
| Lori Lyons-Williams | Director | 26 Jun 2025 | |||
| Evert B. Schimmelpennink | Director | 26 Jun 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|